Corporate Finance
Bergs Securities acted as Sole Manager to Observit in its SEK 26 million directed share issue to Eiffel Investment Group
Bergs Securities acted as financial adviser in the SEK 132m rights issue in Enzymatica
Corporate Finance
Bergs Securities acted as financial adviser in the SEK 132m rights issue in Enzymatica
Enzymatica develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The products are based on the Penzyme® technology, which includes marine enzymes with unique properties. The best-selling product is ColdZyme®, a mouth spray for colds and cold-like symptoms of the upper respiratory tract. ColdZyme has been launched in over 30 markets on four continents. The strategy is to continue to grow by developing more health products, strengthening the company’s position in existing markets and expanding into new geographic markets through established partners.
Related News
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Initiator Pharma Therapeutics in its SEK 56 million rights issue
Corporate Finance
Bergs Securities assisted Smart Eye in the exercise of an incentive program resulting in 497 280 newly issued shares of which around half was divested through a block trade